Skip to main content

Common Major and Mild Neurocognitive Disorders: Alzheimer Disease, Frontotemporal, Lewy Body, and Vascular Types

  • Chapter
  • First Online:
Geriatric Psychiatry Study Guide
  • 1048 Accesses

Abstract

Major and mild neurocognitive disorders are often managed by physicians in multiple specialties including primary practice, psychiatry, geriatric medicine, and neurology. Major and mild neurocognitive disorders are classified according to the known etiological or pathological entities underlying the cognitive impairment. For certain types, the diagnosis depends on the presence of a potentially causative entity, such as Parkinson disease, other parkinsonism, vascular disease, or traumatic brain injury. For other etiologies, such as Alzheimer disease, frontotemporal lobar degeneration, and Lewy body disease, the diagnosis is based primarily on the cognitive, behavioral, and functional symptoms. The differentiation among these multiple types of neurocognitive disorders becomes more evident at the level of major neurocognitive disorder than at the level of mild neurocognitive disorder, but characteristic features can be present at the mild level as well. For many types, international expert groups have developed specialized consensus criteria based on clinicopathological correlation with underlying brain pathology. This section reviews the diagnostic guidelines, clinical presentations, differential diagnosis, and treatment considerations of the four main types: neurocognitive disorder due to Alzheimer disease, frontotemporal neurocognitive disorder, neurocognitive disorder due to Lewy bodies, and vascular neurocognitive disorder.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Roberts RO, Geda YE, Knopman DS, et al. The incidence of MCI differs by subtype and is higher in men: the Mayo Clinic Study of Aging. Neurology. 2012;78(5):342–51.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  2. Ismail Z, Smith EE, Geda Y, et al. Neuropsychiatric symptoms as early manifestations of emergent dementia: provisional diagnostic criteria for mild behavioral impairment. Alzheimers Dement. 2016;12(2):195–202.

    Article  PubMed  Google Scholar 

  3. Ismail Z, Agüera-Ortiz L, Brodaty H, et al. The mild behavioral impairment checklist (MBI-C): a rating scale for neuropsychiatric symptoms in pre-dementia populations. J Alzheimers Dis. 2017;56(3):929–38.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Woolley JD, Khan BK, Murthy NK, Miller BL, Rankin KP. The diagnostic challenge of psychiatric symptoms in neurodegenerative disease; rates of and risk factors for prior psychiatric diagnosis in patients with early neurodegenerative disease. J Clin Psychiatry. 2011;72(2):126–33.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Taragano FE, Allegri RF, Krupitzki H, et al. Mild behavioral impairment and risk of dementia: a prospective cohort study of 358 patients. J Clin Psychiatry. 2009;70:584–92.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Rosenberg PB, Mielke MM, Appleby BS, Oh ES, Geda YE, Lyketsos CG. The association of neuropsychiatric symptoms in MCI with incident dementia and Alzheimer’s disease. Am J Geriatr Psychiatry. 2013;21(7):685–95. https://doi.org/10.1016/j.jagp.2013.01.006.

    Article  PubMed  Google Scholar 

  7. Peters M, Rosenberg P, Steinberg M, et al. Neuropsychiatric symptoms as risk factors for progression from CIND to dementia: the Cache County Study. Am J Geriatr Psychiatry. 2013;21(11):1116–24. https://doi.org/10.1016/j.jagp.2013.01.049.

    Article  PubMed  CAS  Google Scholar 

  8. Pink A, Stokin GB, Bartley MM, et al. Neuropsychiatric symptoms, APOE ε4, and the risk of incident dementia: a population-based study. Neurology. 2015;84(9):935–43.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Petersen RC. Early diagnosis of Alzheimer’s disease: is MCI too late? Curr Alzheimer Res. 2009;6(4):324–30.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Köhler S, Thomas AJ, Barnett NA, O’Brien JT. The pattern and course of cognitive impairment in late-life depression. Psychol Med. 2010;40(4):591–602.

    Article  PubMed  Google Scholar 

  11. Singh-Manoux A, Dugravot A, Fournier A, Abell J, Ebmeier K, Kivimäki M, Sabia S. Trajectories of depressive symptoms before diagnosis of dementia: a 28-year follow-up study. JAMA Psychiatry. 2017;74(7):712–8.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Mirza SS, de Bruijn RF, Direk N, et al. Depressive symptoms predict incident dementia during short- but not long-term follow-up period. Alzheimers Dement. 2014;10(5 Suppl):S323–9.e1.

    Article  PubMed  Google Scholar 

  13. Almeida OP, Hankey GJ, Yeap BB, Golledge J, Flicker L. Depression as a modifiable factor to decrease the risk of dementia. Transl Psychiatry. 2017;7(5):e1117.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Publishing; 2013.

    Book  Google Scholar 

  15. Clark LR, Stricker NH, Libon DJ, et al. Yes/No versus forced-choice recognition memory in mild cognitive impairment and Alzheimer’s disease: patterns of impairment and associations with dementia severity. Clin Neuropsychol. 2012;26(7):1201–16.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Budson AE, Solomon PR. New diagnostic criteria for Alzheimer’s disease and mild cognitive impairment for the practical neurologist. Pract Neurol. 2012;12:88–96.

    Article  PubMed  Google Scholar 

  17. Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614–29.

    Article  PubMed  Google Scholar 

  18. Molin P, Rockwood K. The new criteria for Alzheimer’s disease—implications for geriatricians. Can Geriatr J. 2016;19(2):66–73.

    PubMed  PubMed Central  Google Scholar 

  19. Hategan A, Xiong GL. Major or mild neurocognitive disorder due to Alzheimer disease. In: Hategan, et al., editors. Geriatric psychiatry: a case-based textbook. Springer; 2018, p. 369–401.

    Google Scholar 

  20. Patterson C, Feightner JW, Garcia A, Hsiung G-YR, MacKnight C, Sadovnick AD. Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease. CMAJ. 2008;178(5):548–56.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Rahayel S, Frasnelli J, Joubert S. The effect of Alzheimer’s disease and Parkinson’s disease on olfaction: a meta-analysis. Behav Brain Res. 2012;231(1):60–74.

    Article  PubMed  Google Scholar 

  22. Velayudhan L, Pritchard M, Powell JF, Proitsi P, Lovestone S. Smell identification function as a severity and progression marker in Alzheimer’s disease. Int Psychogeriatr. 2013;25(7):1157–66.

    Article  PubMed  Google Scholar 

  23. Wehling EI, Lundervold AJ, Nordin S, Wollschlaeger D. Longitudinal changes in familiarity, free and cued odor identification, and edibility judgments for odors in aging individuals. Chem Senses. 2016;41(2):155–61.

    PubMed  Google Scholar 

  24. Lafaille-Magnan ME, Poirier J, Etienne P, et al. PREVENT-AD Research Group. Odor identification as a biomarker of preclinical AD in older adults at risk. Neurology. 2017;89(4):327–35.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Growdon ME, Schultz AP, Dagley AS, et al. Odor identification and Alzheimer disease biomarkers in clinically normal elderly. Neurology. 2015;84(21):2153–60.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  26. Doty RL, Shaman P, Dann M. Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function. Physiol Behav. 1984;32(3):489–502.

    Article  PubMed  CAS  Google Scholar 

  27. Doty RL, Frye RE, Agrawal U. Internal consistency reliability of the fractionated and whole University of Pennsylvania Smell Identification Test. Percept Psychophys. 1989;45(5):381–4.

    Article  PubMed  CAS  Google Scholar 

  28. Da Silva MNM, Millington RS, Bridge H, James-Galton M, Plant GT. Visual dysfunction in posterior cortical atrophy. Front Neurol. 2017;8:389. https://doi.org/10.3389/fneur.2017.00389.

    Article  Google Scholar 

  29. Benson DF, Davis RJ, Snyder BD. Posterior cortical atrophy. Arch Neurol. 1988;45(7):789–93.

    Article  PubMed  CAS  Google Scholar 

  30. Tang-Wai DF, Graff-Radford NR, Boeve BF, et al. Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology. 2004;63(7):1168–74.

    Article  PubMed  CAS  Google Scholar 

  31. Caine D. Posterior cortical atrophy: a review of literature. Neurocase. 2004;10(5):382–5.

    Article  PubMed  Google Scholar 

  32. Schmidt C, Wolff M, Weitz M, Bartlau T, Korth C, Zerr I. Rapidly progressive Alzheimer disease. Arch Neurol. 2011;68(9):1124–30.

    Article  PubMed  Google Scholar 

  33. Schott JM, Warren JD. Alzheimer’s disease: mimics and chameleons. Pract Neurol. 2012;12(6):358–66.

    Article  PubMed  Google Scholar 

  34. Blennow K, de Leon MJ, Zetterberg H. Alzheimer’s disease. Lancet. 2006;368(9533):387–403.

    Article  CAS  PubMed  Google Scholar 

  35. Rogan S, Lippa CF. Alzheimer’s disease and other dementias: a review. Am J Alzheimers Dis Other Demen. 2002;17:11–7.

    Article  PubMed  Google Scholar 

  36. Trzepacz PT, Hochstetler H, Wang S, Walker B, Saykin AJ, Alzheimer’s Disease Neuroimaging Initiative. Relationship between the Montreal Cognitive Assessment and Mini-mental State Examination for assessment of mild cognitive impairment in older adults. BMC Geriatr. 2015;15:107. https://doi.org/10.1186/s12877–015–0103–3.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Hollis AM, Duncanson H, Kapust LR, Xi PM, O’Connor MG. Validity of the mini-mental state examination and the montreal cognitive assessment in the prediction of driving test outcome. J Am Geriatr Soc. 2015;63(5):988–92.

    Article  PubMed  Google Scholar 

  38. Gauthier S, Patterson C, Chertkow H, et al. Recommendations of the 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4). Can Geriatr J. 2012;15(4):120–6.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Lee L, Molnar F. Driving and dementia: efficient approach to driving safety concerns in family practice. Can Fam Physician. 2017;63(1):27–31.

    PubMed  PubMed Central  Google Scholar 

  40. Roy M, Molnar F. Systematic review of the evidence for Trails B cut-off scores in assessing fitness-to-drive. Can Geriatr J. 2013;16(3):120–42.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Papandonatos GD, Ott BR, Davis JD, Barco PP, Carr DB. The clinical utility of the trail making tests as predictors of driving performance in older adults. J Am Geriatr Soc. 2015;63(11):2358–64.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Marshall GA, Amariglio RE, Sperling RA, Rentz DM. Activities of daily living: where do they fit in the diagnosis of Alzheimer’s disease? Neurodegener Dis Manag. 2012;2(5):483–91.

    Article  PubMed  Google Scholar 

  43. Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. Lancet. 2017;390(10113):2673–734. https://doi.org/10.1016/S0140-6736(17)31363-6. pii: S0140-6736(17)31363-6.

    Article  PubMed  Google Scholar 

  44. Hsiung GY, Sadovnick AD. Genetics and dementia: risk factors, diagnosis, and management. Alzheimers Dement. 2007;3(4):418–27.

    Article  PubMed  CAS  Google Scholar 

  45. Campion D, Dumanchin C, Hannequin D, et al. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet. 1999;65(3):664–70.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  46. Sleegers K, Roks G, Theuns J, et al. Familial clustering and genetic risk for dementia in a genetically isolated Dutch population. Brain. 2004;127(Pt 7):1641–9.

    Article  PubMed  CAS  Google Scholar 

  47. Rademakers R, Cruts M, Van Broeckhoven C. Genetics of early-onset Alzheimer dementia. Sci World J. 2003;3:497–519.

    Article  CAS  Google Scholar 

  48. Cupples LA, Farrer LA, Sadovnick AD, Relkin N, Whitehouse P, Green RC. Estimating risk curves for first-degree relatives of patients with Alzheimer’s disease: the REVEAL study. Genet Med. 2004;6(4):192–6.

    Article  PubMed  Google Scholar 

  49. Patterson C, Feightner J, Garcia A, MacKnight C. General risk factors for dementia: a systematic evidence review. Alzheimers Dement. 2007;3(4):341–7.

    Article  PubMed  Google Scholar 

  50. National Academies of Sciences, Engineering, and Medicine. Preventing cognitive decline and dementia: a way forward. Washington, DC: The National Academies Press; 2017. https://doi.org/10.17226/24782. Accessed 3 Nov 2017.

    Book  Google Scholar 

  51. Alexopoulos GS, Meyers BS, Young RC, Campbell S, Silbersweig D, Charlson M. ‘Vascular depression’ hypothesis. Arch Gen Psychiatry. 1997;54(10):915–22.

    Article  PubMed  CAS  Google Scholar 

  52. Aizenstein HJ, Baskys A, Boldrini M, et al. Vascular depression consensus report—a critical update. BMC Med. 2016;14(1):161.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Diniz BS, Butters MA, Albert SM, Dew MA, Reynolds CF 3rd. Late-life depression and risk of vascular dementia and Alzheimer’s disease: systematic review and meta-analysis of community-based cohort studies. Br J Psychiatry. 2013;202(5):329–35.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(9):2672–713.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Burhan AM, Moradizadeh M, Marlatt N. Major or mild vascular neurocognitive disorder. In: Hategan, et al., editors. Geriatric psychiatry: a case-based textbook. Springer; 2018, p. 445–66.

    Google Scholar 

  56. Olney NT, Spina S, Miller BL. Frontotemporal dementia. Neurol Clin. 2017;35(2):339–74.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a frontal assessment battery at bedside. Neurology. 2000;55(11):1621–6.

    Article  PubMed  CAS  Google Scholar 

  58. Milan G, Lamenza F, Iavarone A, et al. Frontal Behavioural Inventory in the differential diagnosis of dementia. Acta Neurol Scand. 2008;117(4):260–5.

    Article  PubMed  CAS  Google Scholar 

  59. De Deyn PP, Engelborghs S, Saerens J, et al. The Middelheim Frontality Score: a behavioural assessment scale that discriminates frontotemporal dementia from Alzheimer’s disease. Int J Geriatr Psychiatry. 2005;20:70–9.

    Article  PubMed  Google Scholar 

  60. Bora E, Velakoulis D, Walterfang M. Meta-analysis of facial emotion recognition in behavioral variant frontotemporal dementia: comparison with Alzheimer disease and healthy controls. J Geriatr Psychiatry Neurol. 2016;29(4):205–11.

    Article  PubMed  Google Scholar 

  61. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–9.

    Article  PubMed  Google Scholar 

  62. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47:1113–24.

    Article  PubMed  CAS  Google Scholar 

  63. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies third report of the DLB consortium. Neurology. 2005;65(12):1863–72.

    Article  CAS  PubMed  Google Scholar 

  64. Kales HC, Gitlin LN, Lyketsos CG. Assessment and management of behavioral and psychological symptoms of dementia. BMJ. 2015;350:h369.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Massoud F, Leger G. Pharmacological treatment of Alzheimer disease. Can J Psychiatry. 2011;56(10):579–88.

    Article  PubMed  Google Scholar 

  66. Reisberg B, Ferris SH, de Leon MJ, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry. 1982;139(9):1136–9.

    Article  PubMed  CAS  Google Scholar 

  67. Yorkshire and the Humber Clinical Networks. The assessment of cardiac status before prescribing acetyl cholinesterase inhibitors for dementia. First published April 2016. Reviewed October 2017. http://www.yhscn.nhs.uk/media/PDFs/mhdn/Dementia/ECG%20Documents/ACHEIGuidance%20V1_Final.pdf. Accessed 8 Oct 2017.

  68. Rowland JP, Rigby J, Harper AC, Rowland R. Cardiovascular monitoring with acetylcholinesterase inhibitors: a clinical protocol. Adv Psychiatr Treat. 2007;13(3):178–84.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Hategan, A., Bourgeois, J.A., Cheng, T., Young, J. (2018). Common Major and Mild Neurocognitive Disorders: Alzheimer Disease, Frontotemporal, Lewy Body, and Vascular Types. In: Geriatric Psychiatry Study Guide. Springer, Cham. https://doi.org/10.1007/978-3-319-77128-1_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-77128-1_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-77127-4

  • Online ISBN: 978-3-319-77128-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics